Go to main navigation Go to main content Go to footer

A phase I study to establish the safety and tolerability of arc1905 (anti-c5 aptamer) in subjects with dry age-related macular degeneration

The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injections in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD). Patients were assigned in an alternating fashion to one of two dose levels of ARC1905: 0.3 or 1 mg/eye. Patients were treated with 3 initial intra-vitreal injections of ARC1905 at Day 0, Week 4, Week 8, and a follow-up visit at Week 16. They then received 2 subsequent injections at Week 24 and Week 36, with a final follow-up visit at Week 48. There was a maximum of 5 ARC1905 injections.

untitled

untitled

untitled

untitled

untitled
Pending analysis data. No safety concerns in this phase I intravitreal use for the first time of aptamer anti C5 for geographic atrophy.

Research is the only solution for the future to fight against blindness

It is only with your help that we can fight against blindness

Collaborate